Join
Live feed
·
PRReleasevia Quantisnow
Reviva Pharmaceuticals Holdings Inc. logo

Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia

ByQuantisnow·Wall Street's wire, on your screen.
RVPH· Reviva Pharmaceuticals Holdings Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RVPH (Reviva Pharmaceuticals Holdings Inc.) and more on Quantisnow.